Content about Macula of retina

December 5, 2013

ZeaVision announced that its EyePromise natural supplements are now available for broader distribution through vitamin, health retail and e-tail channels.

CHESTERFIELD, Mo. — ZeaVision on Wednesday announced that its EyePromise natural supplements are now available for broader distribution through vitamin, health retail and e-tail channels.

EyePromise products contain the highest levels of natural zeaxanthin of any eye health supplement, according to ZeaVision. The newest formula, EyePromise vizual EDGE, is based on the success of EyePromise vizual EDGE PRO, popular among professional athletes because it enhances their ability to see objects better and, therefore, react faster.

January 29, 2013

"Talk to your cardiologist." That's the advice offered last week by Wills Eye Institute, a hospital specializing in eye care, following a JAMA article linking aspirin therapy to macular degeneration.

PHILADELPHIA — "Talk to your cardiologist." That's the advice offered Friday by Wills Eye Institute, a hospital specializing in eye care,  following a JAMA article linking aspirin therapy to macular degeneration. 

October 18, 2012

The Food and Drug Administration has approved what it called the first drug to treat an eye condition that can interfere with the part of the retina responsible for reading vision.

SILVER SPRING, Md. — The Food and Drug Administration has approved what it called the first drug to treat an eye condition that can interfere with the part of the retina responsible for reading vision.

The agency announced the approval of Jetrea (ocriplasmin), made by Iselin, N.J.-based ThromboGenics. The drug is used to treat symptomatic vitreomacular adhesion.

September 24, 2012

The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.

TARRYTOWN, N.Y. — The Food and Drug Administration has approved a drug for treating a complication of a disease that results from vein blockages in the eye.

Regeneron Pharmaceuticals announced the approval of Eylea (aflibercept) for treating macular edema following central retinal vein occlusion, or CRVO. Eylea already was approved for treating neovascular age-related macular degeneration, another eye disease.